University of California San Francisco, San Francisco, California, USA.
Columbia University, New York, New York, USA.
Top Antivir Med. 2024 Jul 17;32(3):492-503.
Several novel antituberculosis agents, including long-acting injectable agents in mouse models, have shown promise in preclinical and early clinical studies. This encouraging news is offset by the failures of a tuberculosis (TB) vaccine to prevent disease recurrence and a 3-month clofazimine-based treatment regimen for drug-susceptible TB. Clinically focused insights regarding TB, mpox, and other HIV-associated infectious complications that were presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) are summarized in this review.
几种新型抗结核药物，包括在小鼠模型中具有长效注射作用的药物，在临床前和早期临床研究中显示出前景。这一令人鼓舞的消息被结核（TB）疫苗未能预防疾病复发以及对耐多药结核病采用的为期 3 个月氯法齐明为基础的治疗方案所抵消。在 2024 年逆转录病毒和机会性感染会议（CROI）上提出的关于结核、猴痘和其他与 HIV 相关的传染性并发症的临床重点研究结果在本综述中进行了总结。
